NCT04126460Unknown2 期
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery: The RePASS Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2019年7月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- 1 year disease-free survival
研究概览
简要总结
This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate the efficacy and safety of adjuvant Toripalimab in high-risk recurrent/secondary HNSCC after salvage surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically (histologically or cytologically) confirmed diagnosis of recurrent or second primary squamous cell carcinoma (SCC) of the head and neck. Known p16 status for oropharynx carcinoma.
- •2.Patients must have had prior radiation for head and neck SCC with ≥ 75% of the present tumor volume in areas that have been previously irradiated to at least 45 Gy or the intersection between the first irradiation and the reirradiation fields had to be greater than 65%.
- •Patients with at least one high risk factors after salvage surgery ①positive margin; ②close margin（<5mm); ③ENE;④PNI;⑤LVI; ⑤ rStaging III-IV( AJCC 8th).
- •No macroscopic residual disease after salvage surgery.
- •5.No distant metastasis.
- •6.Eastern Cooperative Oncology Group Performance Status (ECOG) performance scale: 0-
- •7.Adequate organ and bone marrow function: CBC: absolute neutrophil count (ANC) ≥ 1.5 × 10^9 / L; platelet count (PLT) ≥ 80 × 10^9 / L; hemoglobin content (HGB) ≥ 8.0 g / dL.
- •Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.
- •Renal function: serum creatinine (Cr) ≤ 1.5 × ULN.
- •8.Female subject of childbearing potential should have a negative urine or serum pregnancy test < 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •9.Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of study therapy through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses > 1 year.
- •10.Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of the study therapy.
- •11.Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and other requirements of the study.
排除标准
- •Women who are pregnant or lactating.
- •2.Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.
- •3.Subjects who are using systemic immunosuppressive agents and continue the dose within 2 weeks prior to the enrollment.
- •4.Is currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to randomization.
- •5.There have been other malignant tumors in the past 5 years, except the cured skin basal cell carcinoma, cervical carcinoma in situ and superficial bladder cancer.
- •6.Prior therapy with anti-PD-1,anti-PD-L1,anti-CTLA4 antibody.
- •7.Uncontrolled concomitant disease, including but not limited to : Active or poorly controlled severe infection Human Immunodeficiency Virus (HIV) infection (HIV antibody positive) Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection Active tuberculosis Symptomatic congestive heart failure (New York Heart Association grade III-IV) or symptomatic, poorly controlled arrhythmia Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg) Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke, and transient ischemic attack, within 6 months of enrollment.
- •8.Upon the judgment by the investigator, subjects have other factors that possibly cause the halfway-termination of this study, such as other serious illnesses (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, with family or social factors, which may influence the safety of the subject, or the collection of trial data and samples.
研究组 & 干预措施
Toripalimab
Experimental
Injection; dosage form: 6ml: 240mg; frequency: 240mgQ3W; duration: 17cycles (12 months) or randomization to the date of the first documented progression
干预措施: Toripalimab (Drug)
结局指标
主要结局
1 year disease-free survival
时间窗: 1 year
from date of enrollment until date of first documented disease progression or death from any cause, assessed up to 1 year
次要结局
- 1 year local-regional recurrence-free survival(1 year)
- 1 year distant metastasis-free survival(1 year)
- 1 year overall survival(1 year)
- Treatment-related adverse events (AEs)(from the date of enrollment to 90 days after last dose of study treatment)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)Chronic Myeloid LeukemiaDiffuse Large Cell LymphomaMultiple MyelomaLeukemiaChronic Lymphocytic LeukemiaMyelodysplastic SyndromeHodgkin LymphomaNCT00598624IRCCS San Raffaele175
终止
2 期
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)Squamous Cell Carcinoma of Head and NeckNCT05061420Sanofi59
终止
2 期
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).Warm Autoimmune Hemolytic AnemiaNCT04253236Immunovant Sciences GmbH5
终止
2 期
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00801060Biogen40
撤回
2 期
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT03120000PIQUR Therapeutics AG